Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update

RELMADA THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.88

Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.
R&D expense fell to $15.9M from $25.0M, driven by completion of RELIANCE I and III studies.
Cash, cash equivalents, and short-term investments of $132.4M as of March 31, 2023.
Enrollment ongoing in Phase 3 Study 302 (REL-1017 for MDD); completion expected H1 2024.
New Phase 3 Study 304 to start mid-2023 with ~300 patients; completion anticipated H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share, EPS $0.87 per basic and diluted share.

Period: first quarter ended March 31, 2023
Net income: Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share
EPS: $0.87 per basic and diluted share
Result: preliminary results

Exact text from the filing

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-038577

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.